David Liljenquist, MD
Endocrinology, Diabetes & Metabolism · Idaho Falls, IDNPI 1932109931
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.7% of the total across 636 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 58 manufacturers, the largest accounting for just 8.7% — the pattern of someone who eats at a lot of different presentations.
Across 636 payments — averaging $14.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$796
- Novo Nordisk$774
- Amgen$647
- Lilly USA, LLC$632
- Boehringer Ingelheim$559
- Sanofi-aventis U.S. LLC$544
- plus $5K from 52 others
Across 971 payments — averaging $17,327 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Senseonics, Incorporated$5.1M
- Medtronic$3.8M
- Dexcom, Inc.$3.8M
- Abbott$2.6M
- Tandem Diabetes Care, Inc.$555K
- AbbVie$318K
- plus $586K from 5 others
What the payments were for
- Food & beverage$8,90297%
- Education$2713%
- Entertainment$310%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few endocrinology, diabetes & metabolism providers in Idahoto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 695 | $815,081 |
| MounjaroTirzepatide | 653 | $738,907 |
| TrulicityDulaglutide | 288 | $364,521 |
| JardianceEmpagliflozin | 313 | $341,365 |
| FarxigaDapagliflozin Propanediol | 261 | $268,883 |
| Tresiba Flextouch U-100Insulin Degludec | 324 | $229,397 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 179 | $179,782 |
| Tresiba Flextouch U-200Insulin Degludec | 160 | $164,840 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 86 | $93,919 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 524 | $79,857 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 74 | $78,507 |
| EliquisApixaban | 66 | $77,819 |
| RybelsusSemaglutide | 53 | $62,993 |
| Novolog FlexpenInsulin Aspart | 190 | $53,840 |
| Humalog Kwikpen U-100Insulin Lispro | 147 | $51,667 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $632 | $1,130,2611,020 claims |
| Novo NordiskOzempic, Rybelsus, Novolog, Fiasp | $774 | $941,924878 claims |
| Boehringer IngelheimJardiance | $559 | $341,365313 claims |
| AstraZenecaFarxiga | $231 | $268,883261 claims |
| PfizerEliquis, Genotropin | $74 | $118,86991 claims |
| Johnson & JohnsonXarelto, Invokana | $238 | $52,37950 claims |
| Radius Health, Inc.Tymlos | $513 | $48,23918 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Admelog | $544 | $36,47744 claims |
| MerckJanuvia | $53 | $32,26546 claims |
| AmgenEvenity (2 Syringes) | $647 | $25,81111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few endocrinology, diabetes & metabolism providers in Idahoon file to place this against a meaningful peer group, so we don't.
Other endocrinology, diabetes & metabolism in Idaho Falls
- Carl VanceIdaho Falls$729
- John LiljenquistIdaho Falls$480
- Robert EnnisMeridian$69K
- Theodore RooseveltBoise$65K
- Julie FooteBoise$8K
- Katy ConnleyEagle$6K
- Adam LykoPost Falls$5K
- Shanaz SikderBoise$3K
- Angelo CapricchioneBlackfoot$2K
- Michael HolyoakMeridian$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.